taulogo

Company News

 

Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development …  View


Tauriga Sciences, Inc. announced that it has secured additional capital..  View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View

LATEST TAURIGA SCIENCES UPDATES

TAURIGA SCIENCES, INC. RECEIVES NOTIFICATION FROM DTCC THAT THE COMPANY HAS BEEN APPROVED FOR DWAC SERVICES

January 28, 2017NEW YORK, NY–(Marketwired – Jan 27, 2017) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced that it has received approval from The Depository Trust

Read More

Tauriga Sciences, Inc. RolLeaf Branded Product Now Complete; Cannabidiol “CBD” Infused Roll On Product for Muscle Tension Relief

NEW YORK, NY–(Marketwired – Jan 3, 2017) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced it has completed the formulation, graphics, and …

Read More

NEW YORK, NY–(Marketwired – Dec 27, 2016) – Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space, today announced that it has sold an 80% majority stake in its wholly-owned subsidiary, Pilus Energy LLC (“Pilus Energy”), to an Ohio-based company, Open Therapeutics LLC (“Open Therapeutics”).

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

box2
Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
box2a
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
box3
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.